Skip Navigation

Cardiovascular Research 2005 66(3):530-542; doi:10.1016/j.cardiores.2005.02.010
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Robinet, A.
Right arrow Articles by Millart, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robinet, A.
Right arrow Articles by Millart, H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2005, European Society of Cardiology

PI 3-kinase, protein kinase C, and protein kinase A are involved in the trigger phase of β1-adrenergic preconditioning

Arnaud Robinet*, Guillaume Hoizey and Hervé Millart

Department of Pharmacology, Reims University Hospital, 51, rue Cognacq-Jay, 51095, Reims cedex, France

* Corresponding author. Tel.: +33 3 26 91 80 31; fax: +33 3 26 91 35 30. Email address: arnaud.robinet{at}univ-reims.fr

Objective: Using an isolated non-working rat heart model, this study investigated the mechanisms of pharmacological preconditioning (PC) induced by transient β1-adrenoreceptor (β1-AR) stimulation with xamoterol (XA).

Methods: After 6-hydroxydopamine (6-OHDA) pretreatment and a 20-min stabilization period, hearts were perfused at constant pressure for 20 min then subjected to 40 min of global ischemia and 30 min of reperfusion (I/R, Ctrl); exposed to 0.01 µM XA for 5 min with or without 10 µM atenolol (ATE), a specific antagonist of β1-AR, followed by a 15-min XA-free perfusion before I/R (PC, ATE-PC, respectively); treated during 20 min with either phosphoinositide (PI) 3-kinase inhibitors, LY-294002 (LY, 15 µM), or wortmaninn (WO, 0.1 µM); protein kinase C (PKC) inhibitor, GF-109203X (GF, 4 nM); or protein kinase A (PKA) inhibitor, H89 (H89, 1 µM), with an infusion starting 3 min before XA (LY-PC, WO-PC, GF-PC, and H89-PC, respectively). The main endpoints were the mean coronary flow (MCF), the left ventricular end-diastolic pressure (LVEDP), rate-pressure product (RPP), and creatine kinase (CK) release.

Results: XA induced an increase in the MCF after I/R (t 105 min) and a protective effect on the LVEDP, which were blocked by ATE and abolished with the different inhibitors. The transient increase in RPP following XA infusion was blocked by ATE and was not modified by the inhibitors except for H89. Recovery of RPP, measured 25 min after reperfusion, was improved by XA, blocked by ATE, and decreased with the different inhibitors. Fifteen minutes after the end of ischemia, CK release reached maximal values in all groups. XA provided significant protection whereas ATE and the four inhibitors suppressed XA-induced protection.

Conclusion: The transient preischemic exposure to nanomolar concentrations of a β1-AR agonist is protective against I/R. PI 3-kinase, PKC, and PKA are implicated in the trigger phase of PC. These observations were confirmed by Western blots.

KEYWORDS Ischemia; Preconditioning; Protein kinases; Beta1-adrenoreceptor; Signal transduction


Time for primary review 25 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cardiovasc ResHome page
H. Nishida, T. Sato, M. Miyazaki, and H. Nakaya
Infarct size limitation by adrenomedullin: protein kinase A but not PI3-kinase is linked to mitochondrial KCa channels
Cardiovasc Res, January 15, 2008; 77(2): 398 - 405.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
B. Husse, W. Briest, L. Homagk, G. Isenberg, and M. Gekle
Cyclical mechanical stretch modulates expression of collagen I and collagen III by PKC and tyrosine kinase in cardiac fibroblasts
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2007; 293(5): R1898 - R1907.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. N. Peart and G. J. Gross
Cardioprotective effects of acute and chronic opioid treatment are mediated via different signaling pathways
Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1746 - H1753.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
D. K. Arrell, S. T. Elliott, L. A. Kane, Y. Guo, Y. H. Ko, P. L. Pedersen, J. Robinson, M. Murata, A. M. Murphy, E. Marban, et al.
Proteomic Analysis of Pharmacological Preconditioning: Novel Protein Targets Converge to Mitochondrial Metabolism Pathways
Circ. Res., September 29, 2006; 99(7): 706 - 714.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.